InMode (INMD) to Release Earnings on Wednesday

InMode (NASDAQ:INMD) will release its earnings data before the market opens on Wednesday, October 30th. Analysts expect InMode to post earnings of $0.44 per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

InMode (NASDAQ:INMD) last issued its quarterly earnings results on Thursday, August 1st. The healthcare company reported $0.34 EPS for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.04). InMode had a net margin of 35.81% and a return on equity of 21.00%. The business had revenue of $102.60 million for the quarter, compared to analysts’ expectations of $104.81 million. During the same period in the previous year, the business posted $0.65 earnings per share. The business’s revenue was down 24.6% compared to the same quarter last year. On average, analysts expect InMode to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

InMode Trading Up 2.5 %

INMD stock opened at $17.98 on Tuesday. The stock has a market cap of $1.51 billion, a P/E ratio of 8.52 and a beta of 2.17. The stock’s fifty day simple moving average is $16.52 and its two-hundred day simple moving average is $17.34. InMode has a 1-year low of $14.87 and a 1-year high of $26.80.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on INMD shares. Jefferies Financial Group lowered shares of InMode from a “buy” rating to a “hold” rating and reduced their price target for the company from $21.00 to $19.00 in a research report on Tuesday, July 23rd. BTIG Research began coverage on shares of InMode in a research note on Thursday, October 17th. They set a “buy” rating and a $25.00 price target for the company. Barclays dropped their price objective on InMode from $29.00 to $27.00 and set an “overweight” rating on the stock in a research note on Monday, October 14th. Needham & Company LLC reissued a “hold” rating on shares of InMode in a research report on Thursday, October 10th. Finally, Canaccord Genuity Group dropped their price target on InMode from $21.00 to $16.00 and set a “hold” rating on the stock in a research report on Friday, July 12th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, InMode currently has an average rating of “Hold” and a consensus price target of $22.60.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.